Skip to Content

Tavalisse Approval Status

  • FDA approved: No
  • Brand name: Tavalisse
  • Generic name: fostamatinib
  • Company: Rigel Pharmaceuticals, Inc.
  • Treatment for: Immune Thrombocytopenia

Fostamatinib is an investigational oral spleen tyrosine kinase (SYK) inhibitor in development for the treatment of patients with chronic and persistent immune thrombocytopenia (ITP).

Development Status and FDA Approval Process for Tavalisse

DateArticle
Jun 19, 2017FDA Accepts Rigel's New Drug Application for Tavalisse (fostamatinib disodium) for the Treatment of Chronic ITP
Apr 27, 2017Rigel Announces Tavalisse as Proprietary Name for Fostamatinib in the United States
Apr 17, 2017Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP
Aug 30, 2016Rigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP
Feb 25, 2016Rigel Initiates Phase 2 Clinical Trial of Fostamatinib in Autoimmune Hemolytic Anemia
Jun  4, 2013Rigel Will Resume Responsibility for Fostamatinib Program
Jun  4, 2013AstraZeneca: Will Return Fostamatinib Rights to Rigel Pharmaceuticals
Dec 13, 2012AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
Sep 23, 2010Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide